| Target Price | €43.51 |
| Price | €38.43 |
| Potential | 13.23% |
| Number of Estimates | 18 |
| 18 Analysts have issued a price target Qiagen 2027 . The average Qiagen target price is €43.51. This is 13.23% higher than the current stock price. The highest price target is €51.06 32.88% , the lowest is €38.77 0.91% . | |
| A rating was issued by 24 analysts: 12 Analysts recommend Qiagen to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Qiagen stock has an average upside potential 2027 of 13.23% . Most analysts recommend the Qiagen stock at Buy or hold. |
25 Analysts have issued a sales forecast Qiagen 2025 . The average Qiagen sales estimate is €1.8b . This is 2.28% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €1.9b 5.90% , the lowest is €1.7b 3.66% .
This results in the following potential growth metrics:
| 2024 | €1.7b | 0.66% |
|---|---|---|
| 2025 | €1.8b | 7.07% |
| 2026 | €1.9b | 6.14% |
| 2027 | €2.0b | 6.27% |
| 2028 | €2.2b | 10.38% |
| 2029 | €2.4b | 7.93% |
| 2030 | €2.9b | 17.88% |
22 Analysts have issued an Qiagen EBITDA forecast 2025. The average Qiagen EBITDA estimate is €672m . This is 38.87% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €742m 53.38% , the lowest is €580m 19.84% .
This results in the following potential growth metrics and future EBITDA Margins:
| 2024 | €430m | 10.65% |
|---|---|---|
| 2025 | €672m | 56.08% |
| 2026 | €715m | 6.36% |
| 2027 | €779m | 9.03% |
| 2028 | €841m | 8.01% |
| 2029 | €889m | 5.64% |
| 2024 | 25.51% | 9.93% |
|---|---|---|
| 2025 | 37.18% | 45.77% |
| 2026 | 37.26% | 0.22% |
| 2027 | 38.23% | 2.60% |
| 2028 | 37.40% | 2.17% |
| 2029 | 36.61% | 2.11% |
25 Qiagen Analysts have issued a net profit forecast 2025. The average Qiagen net profit estimate is €446m . This is 28.85% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €462m 33.67% , the lowest is €426m 23.19% .
This results in the following potential growth metrics and future Net Margins:
| 2024 | €71.3m | 75.51% |
|---|---|---|
| 2025 | €446m | 524.88% |
| 2026 | €479m | 7.59% |
| 2027 | €526m | 9.65% |
| 2028 | €589m | 12.00% |
| 2029 | €648m | 10.10% |
| 2024 | 4.23% | 75.67% |
|---|---|---|
| 2025 | 24.66% | 483.60% |
| 2026 | 25.00% | 1.38% |
| 2027 | 25.79% | 3.16% |
| 2028 | 26.17% | 1.47% |
| 2029 | 26.70% | 2.03% |
25 Analysts have issued a Qiagen forecast for earnings per share. The average Qiagen EPS is €2.05 . This is 30.57% higher than earnings per share in the financial year 2024. The highest EPS forecast is €2.13 35.67% , the lowest is €1.96 24.84% .
This results in the following potential growth metrics and future valuations:
| 2024 | €0.33 | 74.81% |
|---|---|---|
| 2025 | €2.05 | 521.21% |
| 2026 | €2.21 | 7.80% |
| 2027 | €2.42 | 9.50% |
| 2028 | €2.72 | 12.40% |
| 2029 | €2.99 | 9.93% |
| Current | 24.47 | 80.22% |
|---|---|---|
| 2025 | 18.70 | 23.59% |
| 2026 | 17.38 | 7.06% |
| 2027 | 15.85 | 8.80% |
| 2028 | 14.15 | 10.73% |
| 2029 | 12.85 | 9.19% |
Based on analysts' sales estimates for 2025, the Qiagen stock is valued at an EV/Sales of 4.83 and an P/S ratio of 4.63 .
This results in the following potential growth metrics and future valuations:
| Current | 4.94 | 14.38% |
|---|---|---|
| 2025 | 4.83 | 2.17% |
| 2026 | 4.55 | 5.78% |
| 2027 | 4.28 | 5.90% |
| 2028 | 3.88 | 9.40% |
| 2029 | 3.60 | 7.34% |
| 2030 | 3.05 | 15.17% |
| Current | 4.73 | 14.68% |
|---|---|---|
| 2025 | 4.63 | 2.23% |
| 2026 | 4.36 | 5.78% |
| 2027 | 4.10 | 5.90% |
| 2028 | 3.72 | 9.40% |
| 2029 | 3.44 | 7.34% |
| 2030 | 2.92 | 15.17% |
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Dec 15 2025 |
| Citigroup |
Buy
➜
Neutral
|
Downgrade | Dec 11 2025 |
| Barclays |
Overweight
➜
Overweight
|
Unchanged | Oct 02 2025 |
| UBS |
Neutral
➜
Neutral
|
Unchanged | Aug 07 2025 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Jun 26 2025 |
| Barclays |
➜
Overweight
|
Initiated | Jun 24 2025 |
| Baird |
Neutral
➜
Neutral
|
Unchanged | Apr 21 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Dec 15 2025 |
|
Downgrade
Citigroup:
Buy
➜
Neutral
|
Dec 11 2025 |
|
Unchanged
Barclays:
Overweight
➜
Overweight
|
Oct 02 2025 |
|
Unchanged
UBS:
Neutral
➜
Neutral
|
Aug 07 2025 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Jun 26 2025 |
|
Initiated
Barclays:
➜
Overweight
|
Jun 24 2025 |
|
Unchanged
Baird:
Neutral
➜
Neutral
|
Apr 21 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


